Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2007-07-03
2007-07-03
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
Reexamination Certificate
active
10088632
ABSTRACT:
The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.
REFERENCES:
patent: 5149531 (1992-09-01), Youngner et al.
patent: 6372223 (2002-04-01), Kistner et al.
patent: 0113 665 (1984-07-01), None
patent: WO 94/19013 (1994-09-01), None
patent: WO 95/22989 (1995-08-01), None
patent: WO 00/15251 (2000-03-01), None
patent: WO 00/47222 (2000-08-01), None
patent: 0015251 (2002-03-01), None
Couch et al (Journal of Infectious Diseases 176:S38-S44, 1997).
Chaloupka et al (European Journal of Clinical Microbiology & Infectious Disease 15:121-127, 1996).
Riberdy et al (Journal of Virology 73:1453-1459, 1999).
Davenport et al (Journal of Immunology 100:1139-1140, 1968).
Deliyannis et al (Vaccine 16:2058-2068, 1998).
Kistner et al (Vaccine 16: 960-968, 1998).
De Donato et al (Vaccine 17:3094-3131, Aug. 6, 1999).
Palache et al (Vaccine 11:892-908, 1993).
Brandon et al (Journal of Immunology 98:800-805, 1967).
Montagne et al (Reviews of Infectious Diseases 5:723-727, 1978).
Rimmelzwaan et al (Vaccine 17:1355-1358, Mar. 17, 1999).
Rimmelzwaan et al (Vaccine 17:1355-1358, Mar. 1999).
Enserink. Science 310:1889, 2005.
MacKenzie. Tests dash hope of rapid production of bird flu vaccine. <<ww.newscientist.com/channel/health/bird-flu/dn8478>>, obtained from the internet Feb. 28, 2006.
Gerdil. WHO meetiong on development and evaluation of influenza pandemic vaccines. <<www.who.int/entity/vaccine—research/diseases/influenza/Gerdil.pdf>>, obtained from the internet Feb. 28, 2006.
Lin et al (Lancet 368:991-997, 2006; available online Sep. 7, 2006).
Lu, et al., “A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans”,Journal of Virology, 73(7): 5903-5911 (1999).
Guarnaccia, et al., “A Comparative Immunogenicity-Reactogenicity Dose-Response Study of Influenza Vaccine”,Annals of Allergy, 65: 218-221 (1990).
Kistner, et al., “Development of a Vero Cell-Derived Influenza Whole Virus Vaccine”,Developments in Biological Standardization, 98: 101-110 (1999).
Pressler, et al., “Comparison of the Antigenicity and Tolerance of an Influenza Aluminium Oxide Adsorbate Vaccine with an Aqueous Vaccine”,Pharmatherapeutica, 3(3): 195-200.
Schenk, et al., “Antibody Formulation after Vaccination with Adsorbed and Non-Adsorbed A/New Jersey/8/76 Influenza Vaccines”,Pharmatherapeutica, 3(3): 201-208 (1982).
Bresson, et al., “Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomized trial,”The Lancet, vol. 367, pp. 1657-1664 (2006).
Hehme, et al., “Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use,”Virus Research, vol. 103, pp. 163-171 (2004).
Hehme, et al., “Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines,”Med. Microbiol. Immunol., vol. 191, pp. 203-208 (2002).
Treanor, et al., “Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine,”The New England Journal of Medicine, vol. 354, No. 13, pp. 1343-1351 (2006).
Boger, et al., “Subcutaneous and Intradermal Vaccination with Asian Influenza Vaccine,”J.A.M.A., 1957, 165(13):1687-1689.
Couch, et al., “Improvement of Inactivated Influenza Virus Vaccines,”The Journal of Infectious Diseases, 1997, 176:S38-S44.
Hehme, N.W., “GSK's Pandemic Flu Vaccine Project: Evaluation of H2N2 and H9N2 Candidate Vaccines” GlaxoSmithKline Biologicals,Who Meeting on Development and Evaluation of Influenza Pandemic Vaccines, Geneva, 2005, pp. 1-20.
Kistner, et al., “Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine,”Vaccine, 1998, 16(9/10):960-968.
Kistner, et al., “Development of a Vero Cell-Derived Influenza Whole Virus Vaccine,”Developments in Biological Standardization, 1999, 98:101-110.
La Montagne, et al., “Summary of Clinical Trials of Inactivated Influenza Vaccine,”Reviews of Infectious Diseases, 1983, 5(4):723-736.
Lin, et al., “Safety and Immunogenicity of an Inactivated Adjuvanted Whole-Virion Influenza A (H5N1) Vaccine: A Phase I Randomised Controlled Trial,”The Lancet, 2006, 368:991-997.
Merten, et al., “Production of Influenza Virus in Cell Cultures for Vaccine Preparation,”Advances in Experimental Medicine and Biology, 1996, 397:141-151.
Offit, et al., “Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?”Pediatrics, 2003, 112(6):1394-1401.
Rinella, et al., “Effect of Anions on Model Aluminum-Adjuvant-Containing Vaccines,”Journal of Colloid and Interface Science, 1995, 172:121-130.
Seeber, et al., “Predicting the Absorption of Proteins by Aluminum-Containing Adjuvants,”Vaccine, 1991, 9:201-203.
Shirodkar, et al., “Aluminum Compounds Used as Adjuvants in Vaccines,”Pharmaceutical Research, 1990, 7(12):1282-1288.
Stephenson, et al., “Development of Vaccines Against Influenza H5,”The Lancet, 2006, 6:458-460.
Stephenson, I., “H5N1 Vaccines: How Prepared are we for a Pandemic?”The Lancet, 2006, 368:965-966.
White, et al., Characterization of Aluminum-Containing Adjuvants,Development Biology, 2000, 103:217-228.
“Early Trial Show H5N1 Influenza Vaccine Safe and Effective in Humans at Low Doses,”The Lancet Press Release, 2006.
D'Hondt Erik
Hehme Norbert
Campell Bruce R.
Gimmi Edward R.
Hecht Elizabeth J.
Horning Michelle
Kinzig Charles M.
LandOfFree
Composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810646